Product Description
Moxifloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat and prevent plague (including pneumonic and septicemic plague). Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. (Sourced from: https://www.mayoclinic.org/drugs-supplements/moxifloxacin-oral-route/side-effects/drg-20072313?p=1)
Mechanisms of Action: HERG Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Georgia, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Moldova, Nepal, Netherlands, New Zealand, Pakistan, Peru, Philippines, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, South Korea, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 13
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Conjunctivitis, Bacterial|Endophthalmitis|Fractures, Open|Influenza, Human|Otitis Externa|Pneumonia|Pneumonia, Bacterial|Tuberculosis, Pulmonary
Phase 1: Healthy Volunteers|Multiple Sclerosis|Scleroderma, General
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
NCT07209761 |
QUANTUM-TB | P3 |
Recruiting |
Tuberculosis, Pulmonary |
2027-05-28 |
24% |
2025-12-11 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
2024-11-27 |
||
CTR20241745 |
CTR20241745 | P3 |
Completed |
Pneumonia, Bacterial |
2025-09-16 |
2025-11-09 |
||
2017-002730-23 |
2017-002730-23 | P3 |
Active, not recruiting |
Conjunctivitis, Bacterial |
2017-05-26 |
2025-06-28 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2018-000641-39 |
2018-000641-39 | P2 |
Active, not recruiting |
Otitis Externa |
2020-12-28 |
2025-07-02 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03244072 |
PIND 134134 | P3 |
Not yet recruiting |
Endophthalmitis |
2030-10-01 |
46% |
2025-09-26 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2018-000615-25 |
2018-000615-25 | P3 |
Active, not recruiting |
Otitis Externa |
2015-12-29 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date |
|
CTR20240536 |
CTR20240536 | P1 |
Completed |
Pneumonia, Bacterial |
2024-09-29 |
2025-04-29 |
Primary Completion Date|Start Date|Study Completion Date |
|
NCT06161220 |
IPX203-102-23 | P1 |
Completed |
Healthy Volunteers |
2023-12-03 |
12% |
2024-11-27 |
|
ACTRN12618001390279p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Scleroderma, General|Multiple Sclerosis |
None |
|||
CTR20130195 |
CTR20130195 | P2 |
Recruiting |
Pneumonia |
2013-11-30 |
2025-04-29 |
Patient Enrollment |
|
NCT06846866 |
CN007-1005 | P1 |
Completed |
Healthy Volunteers |
2025-10-21 |
50% |
2025-11-18 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/17/2025 |
News Article |
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025 |
|
05/21/2025 |
News Article |
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies |
|
05/16/2025 |
News Article |
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference |
|
04/24/2025 |
News Article |
Price of Key DR-TB Medicine Drops 25% as TB Alliance's Multi-Manufacturer Strategy Expands Access |